Journals / Sakarya Tıp Dergisi / 2021 / Cilt: 11 - Sayı: 3

The Role of MEG3 in the Activation of Toll Like Receptor 3 in Prostate Cancer Cells

MEG3’ün Prostat Kanseri Hücrelerindeki Toll Benzeri Reseptör 3 Aktivasyonundaki Rolü

Pages
625–630
Publication Date
2021-09-22
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: According to the results, 5 µM of Poly I:C was chosen as a less cytotoxic concentration for the stimulation of TLR3 activity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Prostate cancer accounts for approximately 10% of new cases diagnosed in men worldwide.
📊
Key Findings & Data:Therefore, the aim of this study was to investigate the potential regulatory role of MEG3 and the interaction of TLR3 with MEG3 in the prostate cancer cells.
💡
Conclusion & Impact:Results: According to the results, 5 µM of Poly I:C was chosen as a less cytotoxic concentration for the stimulation of TLR3 activity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Prostat kanseri · TLR3 · MEG3

Abstract

Objective: Prostate cancer accounts for approximately 10% of new cases diagnosed in men worldwide. Toll like receptors (TLRs) play a crucial role in the progression of cancer. Furthermore, the expression level of TLRs is mediated by different transcription factors and non-coding RNAs. Therefore, the aim of this study was to investigate the potential regulatory role of MEG3 and the interaction of TLR3 with MEG3 in the prostate cancer cells. Materials and Methods: In this study, PC-3, LNCaP and HUVEC cells were used. To stimulate TLR3 expression, Poly I:C was used for a ligand of TLR3 and the less cytotoxic concentration of Poly I:C was determined by WST-1 analysis. The relative gene expression levels of TLR3 and MEG3 were analyzed by RT-PCR. Results: According to the results, 5 µM of Poly I:C was chosen as a less cytotoxic concentration for the stimulation of TLR3 activity. The mRNA level of MEG3 (3.19-, 1.90-, and 1.90-fold) and TLR3 (6.17-, 5.75- and 2.27-fold) was significantly increased in PC-3, LNCaP and HUVEC cells, respectively after Poly I:C stimulation (p

Özet

Amaç: Dünya genelinde erkeklerdeki yeni kanser tanılarının yaklaşık %10'unu prostat kanseri oluşturmaktadır. Toll-benzeri reseptörler (TLR), prostat kanseri gelişiminde önemli rol oynamaktadır. Ayrıca TLR’lerin ekspresyon seviyesi çeşitli transkripsiyon faktörleri ve kodlanmayan RNA’lar ile düzenlenmektedir. Bu nedenle bu çalışmada MEG3’ün potansiyel düzenleyici rolünün ve TLR3-MEG3 ilişkisinin belirlenmesi amaçlanmaktadır. Gereç ve Yöntemler: Bu çalışmada PC-3, LNCaP ve HUVEC hücreleri kullanılmıştır. Poli I:C; bir TLR3 ligandı olarak TLR3 ekspresyonunu uyarmak için kullanılmıştır. Poli I:C' nin toksik olmayan konsantrasyonu WST-1 analizi ile belirlenmiştir. TLR3 ve MEG3'ün relatif gen ekspresyon seviyeleri RT-PCR ile analiz edilmiştir. Bulgular: Sonuçlara göre, 5 µM Poli I:C TLR3’ü aktive edilmesi için toksik olmayan konsantrasyon olarak seçilmiştir. MEG3 (3.19-, 1.90- ve 1.90-kat) ve TLR3 (6.17-, 5.75- ve 2.27-kat) mRNA seviyelerinin Poli I:C uygulamasından sonra sırasıyla PC-3, LNCaP ve HUVEC hücrelerinde anlamlı bir şekilde arttığı belirlenmiştir (p

🔖

Cite This Article

İNCE, M. N., ÖZKAN, A. D., BEZDEGÜMELİ, E., MEN, A. Y., KÜÇÜKAKÇA, B. N., ESKİLER, G. G. (2021). The Role of MEG3 in the Activation of Toll Like Receptor 3 in Prostate Cancer Cells. Sakarya Tıp Dergisi, Cilt: 11 - Sayı: 3, 625–630. https://ajindex.com/articles/401483

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Dianat SS, Margreiter M, Eckersberger E, Finkelstein J, Kuehas F, Herwig R, et al. Gene polymorphisms and prostate cancer: the evidence. BJU Int 2009;104:1560-1572
  2. Jemal A, Bray F, Center M M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Cli 2011;61:69-90
  3. Fu W, Yao J, Huang Y, Li Q, Li W, Chen Z, et al. LXR agonist regulates the carcinogenesis of PCa via the SOCS3 pathway. Cell Physiol Biochem 2014;33:195-204
  4. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22;2675-2686
  5. Chang ET, Boffetta P, Adami HO, Cole P, Mandel JS. A critical review of the epidemiology of Agent Orange/ TCDD and prostate cancer. Eur J Epidemiol 2014;29:667-723
  6. Westdorp H, Skold AE, Snijer BA, Franik S, Mulder SF, Major PP, et al. Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol 2014;5:191
  7. Takeda K, Kaisho T, Akira S. Toll-like receptors. Ann Rev Immunol 2003;21:335–76
  8. Carpenter S, Aiello D, Atianand MK, Ricci EP, Gandhi P, Hall LL, et al. A long noncoding RNA mediates both activation and repression of immune response genes. Science 2013;341(6147):789-92
  9. Zhao S, Zhang Y, Zhang Q, Wang F, Zhang D. Toll-like receptors and prostate cancer. Front Immunol 2014;5:352
  10. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, Aguirre A, Suárez A, González JM, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 2011;60: 217–26
  11. Harashima N, Inao T, Imamura R, Okano S, Suda T, Harada M. Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother 2012;61(5):667-76
  12. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010;464:1071-1076
  13. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 2012;9:703-719
  14. Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, et al. LincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 2011;477:295-300
  15. Wang Y, Gao S, Liu G, Jia R, Fan D, Feng X. Microarray expression profile analysis of long non-coding RNAs in human gastric cardiac adenocarcinoma. Cell Physiol Biochem 2014;33:1225-1238
  16. Liu H, Song